A.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. A) Unstained cells. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

B.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. B) Isotype control-FITC. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

C.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. C) Isotype control-PE. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

D.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface marker (anti-CD3-PE). D) CD3+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE in the lymphocyte gate (P1). c) Histogram of anti-CD3-PE in the lymphocyte gate. d) Histogram of anti-CD3-PE in the FITC-channel. e) Dot plots of anti-CD3-PE in the monocyte gate (P5). f) Histogram of anti-CD3-PE in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate and FITC-channel.

E.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface marker (anti-CD19-PE). E) CD19+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE in the lymphocyte gate (P1). c) Histogram of anti-CD19-PE in the lymphocyte gate. d) Histogram of anti-CD19-PE in the FITC-channel. e) Dot plots of anti-CD19-PE in the monocyte gate (P5). f) Histogram of anti-CD19-PE in the monocytes gate. g) Histogram of anti-CD19-PE in the monocyte gate and FITC-channel.

F.a).

d).

c). f).

b).

e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for surface marker (anti-CD56-PE). F) CD56+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE in the lymphocyte gate (P1). c) Histogram of anti-CD56-PE in the lymphocyte gate. d) Histogram of anti-CD56-PE in the FITC-channel. e) Dot plots of anti-CD56-PE in the monocyte gate (P5). f) Histogram of anti-CD56-PE in the monocytes gate. g) Histogram of anti-CD56-PE in the monocyte gate and FITC-channel.

G.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple immunostaining for intracellular NAT2. G) NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-NAT2-FITC in the PE channel. e) Dot plots of anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-NAT2-FITC in the monocyte gate and PE-channel.

H.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. H) Unstained cells. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

I.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. I) Isotype control-FITC. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

J.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface markers (CD3, CD19 or CD56) or for intracellular NAT2. J) Isotype control-PE. a) Dot plots of FSC and SSC. b) Dot plots of the isotype control-FITC in the lymphocyte gate (P1). c) Histogram of isotype control-FITC in the lymphocyte gate. d) Histogram of isotype control-PE in the lymphocyte gate. e) Dot plots of isotype control-FITC in the monocyte gate (P5). f) Histogram of isotype control-FITC in the monocytes gate. g) Histogram of isotype control-PE in the monocyte gate.

K.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface marker (anti-CD3-PE). K) CD3+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE in the lymphocyte gate (P1). c) Histogram of anti-CD3-PE in the lymphocyte gate. d) Histogram of anti-CD3-PE in the FITC-channel. e) Dot plots of anti-CD3-PE in the monocyte gate (P5). f) Histogram of anti-CD3-PE in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate and FITC-channel.

L.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface marker (anti-CD19-PE). L) CD19+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE in the lymphocyte gate (P1). c) Histogram of anti-CD19-PE in the lymphocyte gate. d) Histogram of anti-CD19-PE in the FITC-channel. e) Dot plots of anti-CD19-PE in the monocyte gate (P5). f) Histogram of anti-CD19-PE in the monocytes gate. g) Histogram of anti-CD19-PE in the monocyte gate and FITC-channel.

M.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for surface marker (anti-CD56-PE). M) CD56+ lymphocytes. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE in the lymphocyte gate (P1). c) Histogram of anti-CD56-PE in the lymphocyte gate. d) Histogram of anti-CD56-PE in the FITC-channel. e) Dot plots of anti-CD56-PE in the monocyte gate (P5). f) Histogram of anti-CD56-PE in the monocytes gate. g) Histogram of anti-CD56-PE in the monocyte gate and FITC-channel.

N.a).

d).

c). f).

b). e).

g).

Figure S1. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were simple immunostaining for intracellular NAT2. N) NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-NAT2-FITC in the PE channel. e) Dot plots of anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-NAT2-FITC in the monocyte gate and PE-channel.

A.a).

d).

c). f).

b). e).

g).

Figure S2. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. A) CD3+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD3-PE in the lymphocyte gate. e) Dot plots of anti-CD3-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate.

B.a).

d).

c). f).

b). e).

g).

Figure S2. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. B) CD19+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD19-PE in the lymphocyte gate. e) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD19-PE in the monocyte gate.

C.a).

d).

c). f).

b). e).

g).

Figure S2. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. C) CD56+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD56-PE in the lymphocyte gate. e) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD56-PE in the monocyte gate.

D.a).

d).

c). f).

b). e).

g).

Figure S2. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. D) CD3+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD3-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD3-PE in the lymphocyte gate. e) Dot plots of anti-CD3-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD3-PE in the monocyte gate.

E.a).

d).

c). f).

b). e).

g).

Figure S2. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. E) CD19+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD19-PE in the lymphocyte gate. e) Dot plots of anti-CD19-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD19-PE in the monocyte gate.

F.a).

d).

c). f).

b). e).

g).

Figure S2. NAT2 expression in lymphocytes and monocytes from a tuberculosis patient. PBMC from a tuberculosis patient were double immunostaining for surface markers (CD3, CD19 or CD56) and for intracellular NAT2. F) CD56+NAT2+ cells. a) Dot plots of FSC and SSC. b) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the lymphocyte gate (P1). c) Histogram of anti-NAT2-FITC in the lymphocyte gate. d) Histogram of anti-CD56-PE in the lymphocyte gate. e) Dot plots of anti-CD56-PE and anti-NAT2-FITC in the monocyte gate (P5). f) Histogram of anti-NAT2-FITC in the monocytes gate. g) Histogram of anti-CD56-PE in the monocyte gate.

Figure S3. Negative and Positive controls for NAT2 immunostaining protocol. CHO cells were used as a negative control of NAT2 expression (A-G). HeLa cells were used as a positive control of NAT2 expression (H-N). Dot plots of FSC and SSC for CHO (A) and HeLa cells (H). Dot plots of unstained CHO (B) and HeLa cells (I). Histograms of the unstained CHO (C) and HeLa cells (J). Dot plots of the isotype control-FITC in CHO (D) and HeLa cells (K). Histograms of the isotype control-FITC in CHO (E) and HeLa cells (L). Dot plots of anti-NAT2-FITC in CHO (F) and HeLa cells (M). Histograms of anti-NAT2-FITC in CHO (G) and HeLa cells (N).

A.

G.F.

E.D.

C.B.

H.

N.M.

L.K.

J.I.